Cationic Polythiophene as Gene Carrier and Sonosensitizer for Sonodynamic Synergic Gene Therapy of Hepatocellular Carcinoma

被引:0
|
作者
Chen, Yongzhi [1 ]
Pang, E. [2 ]
Peng, Rui [1 ]
Tang, Yuanyu [2 ]
Tan, Qiuxia [2 ]
Lan, Minhuan [2 ]
Bai, Dousheng [1 ]
机构
[1] Yangzhou Univ, Clin Med Coll, Dept Hepatobiliary Surg, Yangzhou 225009, Jiangsu, Peoples R China
[2] Cent South Univ, Coll Chem & Chem Engn, Hunan Prov Key Lab Micro & Nano Mat Interface Sci, Changsha 410083, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
cationic polythiophene; sonodynamic therapy; gene therapy; hepatocellularcarcinoma; siRNA; NANOPARTICLES;
D O I
10.1021/acsbiomaterials.4c00704
中图分类号
TB3 [工程材料学]; R318.08 [生物材料学];
学科分类号
0805 ; 080501 ; 080502 ;
摘要
Hepatocellular carcinoma (HCC) is one of the most lethal and highly malignant tumors. Sonodynamic therapy (SDT) is a new cancer treatment method. One of its unique advantages lies in the treatment of deep tumors due to its excellent tissue penetration ability caused by ultrasound (US). However, most sonosensitizers suffer from weak sonodynamic activity and poor tumor-targeting ability. In addition, small interfering RNA (siRNA) is a promising anticancer drug, and the efficacy of siRNA-based gene therapy largely depends on the cell impermeability of the gene carrier. Here, we designed and synthesized a cationic polythiophene derivative (PT2) that can be used as a siRNA carrier for gene therapy. Moreover, PT2 could generate singlet oxygen (O-1(2)) and hydroxyl radicals (O-2(center dot-)) under US irradiation, which suggests that PT2 could be used for SDT. Our study discovered that NUDT1 promoted HCC proliferation and inhibited intracellular ROS production. Therefore, si-NUDT1 was designed and synthesized. NUDT1 silencing can inhibit the proliferation of tumor cells and increase the production of intracellular ROS to further improve the efficacy of SDT. Then, si-NUDT1 assembled with PT2 and DSPE-PEG-FA to prepare a novel tumor-targeting nanodrug (PT2-siRNA@PEG-FA) for synergic SDT and gene therapy of HCC.
引用
收藏
页码:4601 / 4611
页数:11
相关论文
共 50 条
  • [31] Hepatocellular carcinoma and p53 gene therapy
    Fricker, J
    MOLECULAR MEDICINE TODAY, 1996, 2 (09): : 361 - 361
  • [32] p53 and gene therapy for hepatocellular carcinoma
    Habib, NA
    Mitry, RR
    Sadri, R
    GENE THERAPY OF CANCER, 1998, 451 : 499 - 504
  • [33] Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma
    Mckiver, Bryan
    Damaj, Mohamad Imad
    Sarkar, Devanand
    GASTROINTESTINAL DISORDERS, 2020, 2 (04): : 469 - 480
  • [34] Nis-based gene therapy of hepatocellular carcinoma
    Herve, J
    Liu, B
    Gerolami, R
    Kamsu-Kom, N
    Longuet, M
    Cunha, AS
    Válogne, Y
    Roux, J
    Clerc, I
    Brechot, C
    Faivre, J
    JOURNAL OF HEPATOLOGY, 2005, 42 : 139 - 139
  • [35] Survivin, the promising target in hepatocellular carcinoma gene therapy
    Liu, Jie
    Du, Wenqi
    Fan, Daiming
    CANCER BIOLOGY & THERAPY, 2008, 7 (04) : 555 - 556
  • [36] Combined suicide/cytokine gene therapy of hepatocellular carcinoma
    Stefani, AL
    Barzon, L
    Castagliuolo, I
    Guido, M
    Farinati, F
    Palù, G
    MOLECULAR THERAPY, 2004, 9 : S226 - S226
  • [37] Suicide gene therapy of hepatocellular carcinoma and delivery procedure and route of therapeutic gene in vivo
    Xiao-Yi Sun
    Zai-De Wu
    Jun-Bo Hu the Department of Surgery
    Hepatobiliary & Pancreatic Diseases International, 2002, (03) : 373 - 377
  • [38] Specifically Deoxyribozyme of the PTPRO gene as a potential gene therapy means for human hepatocellular carcinoma
    Su, Chunnian
    Yu, Min
    ADVANCES IN CHEMICAL ENGINEERING III, PTS 1-4, 2013, 781-784 : 1203 - 1208
  • [39] Transcriptional targeted gene therapy for hepatocellular carcinoma by adenovirus vector
    Kanai, F
    MOLECULAR BIOTECHNOLOGY, 2001, 18 (03) : 243 - 250
  • [40] Restriction of tumoricidal gene therapy to selected hepatocellular carcinoma cells
    Gagandeep, S
    Gupta, S
    HEPATOLOGY, 1996, 24 (05) : 1317 - 1319